HUE029564T2 - Herpes simplex vírus vakcinák - Google Patents

Herpes simplex vírus vakcinák Download PDF

Info

Publication number
HUE029564T2
HUE029564T2 HUE10840033A HUE10840033A HUE029564T2 HU E029564 T2 HUE029564 T2 HU E029564T2 HU E10840033 A HUE10840033 A HU E10840033A HU E10840033 A HUE10840033 A HU E10840033A HU E029564 T2 HUE029564 T2 HU E029564T2
Authority
HU
Hungary
Prior art keywords
hsv
sequence
promoter
mice
infection
Prior art date
Application number
HUE10840033A
Other languages
English (en)
Inventor
Feng Yao
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of HUE029564T2 publication Critical patent/HUE029564T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C12N15/8695—Herpes simplex virus-based vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16061—Methods of inactivation or attenuation
    • C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus

Claims (4)

  1. Herpes simplex vírus vakcinák SZABADALMI IGÉNYPONTOK.
    1, Replikáeii'-defektiv. dommáns-negatlv Herpes simplex vims 2: (IÏSV-2) rekombiráns virus, amely a genomjâban a következőket tartalmazza: a) : egy első szekvencia, amely egy első BSY-2 glíkoprotek D~t ígD2) kódol, ahol a szóban forgó szekvencia mikddés szempontjából egy első tei-ö-tartalmn HSY-1 €P4 promoterhez van kapcsolva; b) egy második szekvencia, amely egy második BSV-2 gD2-t kódol:, ahol a szóban forgó második szekvencia mnbödés szempontjából egy második tei-GAartalmú HSV-1 €P4 pvmm-terhez, van kapcsolva* e) egy harmadik szekvencia, amely egy első ül,9 C33SC felsőjét (2. számé szekvencia) kódol, ahol a szóba® lorgó harmadik szekvencia működés szempontjából egy első iet-Ö-lartalmú feCMV közvetlen közeli prornotérhez kapcsolódik, a teljes hosszúságú: promoter -236 bázis-párjánál egy csonkítással; és á) egy negyedik szekvencia, amely egy második 111,9 CS35C lobért# (2. számó szekvencia) kódol, aboi a szóban íorgő negyedik szekvencia működés szempontjából egy második lei-Ö-lartainiű hCMV közvetlen közel promoterhez kapcsolódik», a teljes hosszúságú promoter -236 bázispártjánál egy csonkítással; is ahol a szóban lorgó genom nem tartalmaz funkcionális iCPO iebéfjét. kódoló szekvenciái 2v Az I. igénypont .szerinti rekornbináns vírus, ahol: a) a. szóban forgó első és második tet-O-tartalmn 1ISY-1 CP4 promoterek, és a szóban íórgő első és második tet-Ö-íanalmú hCMV közvetlen közeli promoterek egyaránt rendelkeznek egy TATA elemmel; b) mindegyik szóban, forgó let A3-tartalmú promofer-szekveneia tartalmaz két op2 repressxor-: koto helyet, amelyeket 2-20 összekötő mádeotid kapcsol össze, ahol a szóban forgó tét operátorban m első ntáleotid a. 6. és 24. imkleotid közön található, a szóban forgó TATA elem utolsó nukleoiidjáíól 3' irányban; c) a szóban forgó első szekvencia, «amely egy HSV-2 gD2~l kódol., és a szóban forgó második szekvencia, amely egy HSV-2 gD2~t kódok a szóban forgó első és második Tet-O-tartalmá HSV-i CF4 promoterekhez viszonyítva 3 ’ irányban: helyezkedik el; d| a szóban forgó harmadik szekvencia, amely egy UL9 C535C fehérjéi (2. számú szekvencia) kódok és a szóban forgo 4, szekvencia, amely egy IJL9 CS35C ledénél (2. számú szekvencia) kódok a szóban forgó tet-Ö-tarlaimá i€MV közvetlen közeli pomoterekhez viszonyítva 3' irányban helyezkedik el...
  2. 3. Az 1. vagy 2. igénypont szerinti rekömbiafe 'vírus,, amely egy vagy több rekonfoinfeis Immun® odolále gént is enpresszáL példán! ILI 2-t vagy IL-IS-ot HSY-2 gB-í a letö-hordozó BSV vagy h€MY közvetlen-közeli promoter vezérlése alatt; és/vagy HSV-2 gC-t a tetO-lmrdozó BSV vagy hCMV közvetlen-közeli promoter vezérlése alatt 4:. Az 1. vagy 2. igénypont bármelyike szerinti rekomblnáps viras, amely a HSV-2 gB-i a tető-hordozó BSV vagy k€MV közvetlen-közeli promoter vezérlése alatt ezptesszáija.
  3. 5. Az 14. igénypontok bármelyike szerinti rekombináns vírus ahol a szóban lorgo harmadik, az UL9 €535C fehérjéi (2. szántó szekvencia) kódoló szekvencia transzkrípciqja. és a szóban forgó első. a HSV-2 gD2-t kódoló szekveneia. transzkripebija ellentétes orientációjú, és ahol a szóban .forgó negyedik, az ÜL9 C535C fehérjét (2, számú szekvencia) kódoló szekvencia transzkripciója és a sfobmvforgó második, a H SV-2 gD2-t kódoló szekveneia transzkripciója ellentétes orientációjú. 6. .½ 1-4, igénypontok bármelyike szerinti rekombináns vires, ahol az ICF4 ptonroierek-bői hiányzik egy 1CP4 DNS-kötő szekveneia.
  4. 7. Vakcina, amel}· az l-δ. igénypontok bármelyike szerinti rekombináns vírust tartalmazza, egységdózis formájába® 8. A 7, igénypont szerintii vakcina, amelyben a rekombináns vírus minimum IvlCk tarfbltképzo egység per egységdözis mennyiségben van jelen, példád 1 *.10"' - 1 ^ 1.0* per egységdózis mennyiségben, 9. A ?.. vagy 8, igénypont szerinti vakcina, egy beteg BSV-I vagy HSV-2 fertőzés elleni tmni nnízálásábaxí történő aik aim ázást® 10. A 7. vagy S. igénypont szerinti vakcina 9. igénypont szerinti alkalmazása, aboi a beteg: szeropozhiv a HSV-1, szeropozitiv a HSV-2, szcrogoziiív mind a HSV-L mind a HSV-2 fertőzésre, \agy szeronegativ a HSY-1 és HSV-2 fertőzésre.
HUE10840033A 2009-12-21 2010-12-20 Herpes simplex vírus vakcinák HUE029564T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28883609P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
HUE029564T2 true HUE029564T2 (hu) 2017-03-28

Family

ID=44196388

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10840033A HUE029564T2 (hu) 2009-12-21 2010-12-20 Herpes simplex vírus vakcinák

Country Status (19)

Country Link
US (3) US8809047B2 (hu)
EP (1) EP2516629B1 (hu)
JP (2) JP5845191B2 (hu)
KR (1) KR101747987B1 (hu)
CN (1) CN102666843B (hu)
AU (1) AU2010333749B2 (hu)
BR (1) BR112012015172A2 (hu)
CA (1) CA2783330A1 (hu)
DK (1) DK2516629T3 (hu)
HK (1) HK1175807A1 (hu)
HR (1) HRP20160573T1 (hu)
HU (1) HUE029564T2 (hu)
PL (1) PL2516629T3 (hu)
PT (1) PT2516629T (hu)
RS (1) RS54933B1 (hu)
SI (1) SI2516629T1 (hu)
SM (1) SMT201600187B (hu)
WO (1) WO2011079073A2 (hu)
ZA (1) ZA201204192B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8796440B2 (en) 2009-08-31 2014-08-05 The Brigham And Women's Hospital, Inc. Promote system for regulatable gene expression in mammalian cells
CN102666843B (zh) 2009-12-21 2014-10-22 布里格海姆妇女医院公司 单纯疱疹病毒疫苗
ES2914081T3 (es) * 2014-08-26 2022-06-07 Hsf Pharmaceuticals Agentes de inmunización y métodos de uso novedosos
KR102227180B1 (ko) * 2017-03-09 2021-03-12 시아먼 유니버시티 재조합 헤르페스 심플렉스 바이러스 및 이의 용도
US20200172928A1 (en) * 2017-06-05 2020-06-04 The Brigham And Women's Hospital, Inc. Vero cell lines stably expressing hsv icp0 protein
WO2019152821A1 (en) * 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
US20210324483A1 (en) 2018-10-15 2021-10-21 Regenxbio Inc. Method for measuring the infectivity of replication defective viral vectors and viruses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE69328514T2 (de) * 1992-03-13 2001-01-11 Monsanto Co Herstellung rekombinanter Proteine unter Verwendung von Herpes-Virus-Promotoren und VP16-Transaktivatoren
US6183753B1 (en) * 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
CA2143326A1 (en) 1992-08-26 1994-03-03 Guerard Byrne Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
US5965440A (en) 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
WO2001053505A2 (en) 2000-01-21 2001-07-26 Biovex Limited Herpes virus strains for gene therapy
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US6846670B2 (en) * 2000-11-28 2005-01-25 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US20040029229A1 (en) 2002-05-20 2004-02-12 Reeves Philip J. High level protein expression system
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
CA2500270A1 (en) * 2002-09-27 2004-04-08 Powderject Research Limited Nucleic acid constructs for gene expression
US7335763B2 (en) 2003-03-25 2008-02-26 University Of Florida Research Foundation, Inc. Herpesvirus ribozymes and vectors
US20040229362A1 (en) * 2003-05-15 2004-11-18 Alberto Epstein Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors
US9273326B2 (en) * 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8796440B2 (en) * 2009-08-31 2014-08-05 The Brigham And Women's Hospital, Inc. Promote system for regulatable gene expression in mammalian cells
CN102666843B (zh) 2009-12-21 2014-10-22 布里格海姆妇女医院公司 单纯疱疹病毒疫苗

Also Published As

Publication number Publication date
KR101747987B1 (ko) 2017-06-15
HK1175807A1 (zh) 2013-07-12
BR112012015172A2 (pt) 2017-03-07
ZA201204192B (en) 2013-02-27
CN102666843A (zh) 2012-09-12
SI2516629T1 (sl) 2016-10-28
PT2516629T (pt) 2016-07-07
HRP20160573T1 (hr) 2016-09-23
JP5845191B2 (ja) 2016-01-20
US9408905B2 (en) 2016-08-09
WO2011079073A2 (en) 2011-06-30
US20120263752A1 (en) 2012-10-18
RS54933B1 (sr) 2016-10-31
WO2011079073A3 (en) 2012-02-02
SMT201600187B (it) 2016-11-10
US8809047B2 (en) 2014-08-19
EP2516629A4 (en) 2013-09-04
AU2010333749B2 (en) 2015-07-30
DK2516629T3 (en) 2016-07-04
EP2516629B1 (en) 2016-04-13
PL2516629T3 (pl) 2016-11-30
CN102666843B (zh) 2014-10-22
RU2012131167A (ru) 2014-01-27
AU2010333749A1 (en) 2012-06-14
JP2013514784A (ja) 2013-05-02
US20140314811A1 (en) 2014-10-23
JP2015144619A (ja) 2015-08-13
EP2516629A2 (en) 2012-10-31
CA2783330A1 (en) 2011-06-30
US20170028058A1 (en) 2017-02-02
KR20120095450A (ko) 2012-08-28

Similar Documents

Publication Publication Date Title
EP2516629B1 (en) Herpes simplex virus vaccines
US8501194B2 (en) Vaccine for viruses that cause persistent or latent infections
AU6261794A (en) Defective mutant non-retroviral virus (e.g. hsv) as vaccine
JP6652497B2 (ja) 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター
Akhrameyeva et al. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice
Aschner et al. Alphaherpesvirus vaccines
Prichard et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs
US5837261A (en) Viral vaccines
US11390650B2 (en) Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
Brans et al. Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1
Lu et al. High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection
US20150359878A1 (en) Use of replication deficient hsv-1 as a vaccine vector for the deli vary of hiv-1 tat antigen
Braun et al. Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments
Hirano et al. Efficacy of a B virus gD DNA vaccine for induction of humoral and cellular immune responses in Japanese macaques
ES2577704T3 (es) Vacunas de virus herpes simple
US20240156954A1 (en) Vaccine compositions and methods for treating hsv
RU2575067C2 (ru) Вакцины против вируса простого герпеса
Ďurmanová et al. Herpes simplex virus 1 and 2 vaccine design: What can we learn from the past
Koelle et al. Herpes Simplex Vaccines